OCTS EU 2022

OCTS EU 2022

Bringing together cell therapy specialists to develop more efficacious therapies and efficient vein-to-vein processes

Download agenda
LONDON, UK
1-3 November, 2022

“Virtual events are not easy and this one is done flawlessly. Having world class presentations beamed into your home and the ability to ask live questions is fantastic.”

PHC

Why Attend

Following the success of our first digital event in July 2021 with the likes of Carl June leading the keynote, the Onco Cell Therapy Summit is returning in its most interactive form ever with 20+ panel conversations, townhall meetings, roundtable sessions and coffee break style networking.

The Global Onco Cell Therapy Summit provides a platform for information sharing to enable the discovery, translation and commercialization of cell therapies in oncology by connecting senior representatives in pharma, biotechs and academia. The summit will address the research, regulatory, logistical and technical challenges that are holding back the field.

Delve into how thought leaders in cell therapy are addressing threats and opportunities to bring effective therapies to the market through:

  • Meeting efficacies and safety targets as well as the scale of demands.
  • Discovering the latest advances in the journey towards effective allogeneic and solid tumor targeting therapies.
  • Overcoming the challenging in scale up and automation of manufacturing
  • Round table discussions on vectors and the promise of non-viral approaches.
  • Reimbursment strategies and their link to the latest developments in safety trials and regulatory standards 

Whilst bringing together the key decision makers for oncological cell therapies, this year’s summit will have an added focus on the data releases and mergers that are driving the surge of interest in harnessing alternative cell therapies in cancer treatments.

Mission Statement

With 5 CAR-T therapies now approved, the cell therapy market is starting to move through its nascent stages. As of the start of 2021, there are another 23 candidates in phase III clinical trials. As the competition between approved cell therapies becomes available to patients, differentials in price and efficacy become front of mind.

The Onco Cell Therapy Summit returns to the EU in 2022 to address issues in scale-up and out of next-generation therapies and explore the translation of R&D through the clinic to revolutionize patient outcomes in oncology.

2021 Speakers

 

Adrian Bot

VP Translational Medicine
Kite Pharma

Adrian Bot

VP Translational Medicine
Kite Pharma

Adrian Bot

VP Translational Medicine
Kite Pharma
 

Dr. Christina Coughlin

Chief Medical Officer & Executive Vice President
Tmunity

Dr. Christina Coughlin

Chief Medical Officer & Executive Vice President
Tmunity

Dr. Christina Coughlin

Chief Medical Officer & Executive Vice President
Tmunity
 

Michael Hudecek

Director CAR-T Program
Universitätsklinikum Würzburg, Germany

Michael Hudecek

Director CAR-T Program
Universitätsklinikum Würzburg, Germany

Michael Hudecek

Director CAR-T Program
Universitätsklinikum Würzburg, Germany
 

Jason Litten

CMO
Artiva

Jason Litten

CMO
Artiva

Jason Litten

CMO
Artiva
 

Dan Kaufman

Professor of Medicine – Division of Regenerative Medicine
UCSD

Dan Kaufman

Professor of Medicine – Division of Regenerative Medicine
UCSD

Dan Kaufman

Professor of Medicine – Division of Regenerative Medicine
UCSD
 

Alice Brown

VP Research
GammaDelta Therapeutics

Alice Brown

VP Research
GammaDelta Therapeutics

Alice Brown

VP Research
GammaDelta Therapeutics
 

John Rossi

Senior Director
Kite Pharma

John Rossi

Senior Director
Kite Pharma

John Rossi

Senior Director
Kite Pharma
 

Dr Detlev Parow

Head of Department of Medicines, Therapeutic Appliances and Remedies
DAK-Gesundheit

Dr Detlev Parow

Head of Department of Medicines, Therapeutic Appliances and Remedies
DAK-Gesundheit

Dr Detlev Parow

Head of Department of Medicines, Therapeutic Appliances and Remedies
DAK-Gesundheit
 

Evren Alici

CEO
Vycellix

Evren Alici

CEO
Vycellix

Evren Alici

CEO
Vycellix
 

Prof. Torsten Tonn

Group Leader
Univesitat Dresden

Prof. Torsten Tonn

Group Leader
Univesitat Dresden

Prof. Torsten Tonn

Group Leader
Univesitat Dresden
 

Deepak Raj

Centre for Tumour Biology
Bart's Cancer Institute

Deepak Raj

Centre for Tumour Biology
Bart's Cancer Institute

Deepak Raj

Centre for Tumour Biology
Bart's Cancer Institute
 

Nick Huntington

Co-Founder and CSO
oNKo Innate

Nick Huntington

Co-Founder and CSO
oNKo Innate

Nick Huntington

Co-Founder and CSO
oNKo Innate
 

Blake Aftab

VP Preclinical and Translational Sciences
Atara Biotherapeutics

Blake Aftab

VP Preclinical and Translational Sciences
Atara Biotherapeutics

Blake Aftab

VP Preclinical and Translational Sciences
Atara Biotherapeutics
 

James Patterson

Founder
Auxolytic

James Patterson

Founder
Auxolytic

James Patterson

Founder
Auxolytic
 

Frank Thielmann

Director of Operational Excellence
Takeda

Frank Thielmann

Director of Operational Excellence
Takeda

Frank Thielmann

Director of Operational Excellence
Takeda
 

Eytan Breman

R&D Manager
Celyad Oncology

Eytan Breman

R&D Manager
Celyad Oncology

Eytan Breman

R&D Manager
Celyad Oncology
 

Tony Ho

Executive Vice President – Head of Research and Development
CRISPR Therapeutics

Tony Ho

Executive Vice President – Head of Research and Development
CRISPR Therapeutics

Tony Ho

Executive Vice President – Head of Research and Development
CRISPR Therapeutics
 

Steven Kanner

CSO
Caribou Biosciences

Steven Kanner

CSO
Caribou Biosciences

Steven Kanner

CSO
Caribou Biosciences
 

Hong Ma

CARsgen

Hong Ma

CARsgen

Hong Ma

CARsgen
 

Hanspeter Gerber

CSO
3T Biosciences

Hanspeter Gerber

CSO
3T Biosciences

Hanspeter Gerber

CSO
3T Biosciences
 

Volker Huppert

COO
Glycostem

Volker Huppert

COO
Glycostem

Volker Huppert

COO
Glycostem
 

Robert Kochl

Group Leader
Kings College London

Robert Kochl

Group Leader
Kings College London

Robert Kochl

Group Leader
Kings College London
 

Darrell Irvine

Professor of Materials Science
MIT

Darrell Irvine

Professor of Materials Science
MIT

Darrell Irvine

Professor of Materials Science
MIT
 

Professor Graham Pockley

Director
John van Geest Research Centre, Nottingham Trent University

Professor Graham Pockley

Director
John van Geest Research Centre, Nottingham Trent University

Professor Graham Pockley

Director
John van Geest Research Centre, Nottingham Trent University
 

Stephen Feldman

Director of Manufacturing and Process Development
Stanford Center for Cancer Cell Therapy

Stephen Feldman

Director of Manufacturing and Process Development
Stanford Center for Cancer Cell Therapy

Stephen Feldman

Director of Manufacturing and Process Development
Stanford Center for Cancer Cell Therapy
 

Dr John Maher

Clinical Senior Lecturer/Honorary Consultant/CSO
King's College London/Leucid Bio

Dr John Maher

Clinical Senior Lecturer/Honorary Consultant/CSO
King's College London/Leucid Bio

Dr John Maher

Clinical Senior Lecturer/Honorary Consultant/CSO
King's College London/Leucid Bio
 

Reagan Jarvis

CEO & Co-Founder
Anocca AB

Reagan Jarvis

CEO & Co-Founder
Anocca AB

Reagan Jarvis

CEO & Co-Founder
Anocca AB
 

Professor Ann Ager

Personal Chair, School of Medicine
Cardiff University

Professor Ann Ager

Personal Chair, School of Medicine
Cardiff University

Professor Ann Ager

Personal Chair, School of Medicine
Cardiff University
 

Paul Rennert

President and CSO
Aleta Biotherapeutics

Paul Rennert

President and CSO
Aleta Biotherapeutics

Paul Rennert

President and CSO
Aleta Biotherapeutics
 

Dan Shelly

VP of Development
Prescient Therapeutics

Dan Shelly

VP of Development
Prescient Therapeutics

Dan Shelly

VP of Development
Prescient Therapeutics
 

Kenneth Warrington

Sr. Director, Business Development,
GenScript ProBio

Ken Warrington, PhD joined GenScript Probio in 2020 as Head of Strategy & Innovation and a Sr. Director of Business Development supporting their Gene & Cell Therapy CMC services.  Dr.

Kenneth Warrington

Sr. Director, Business Development,
GenScript ProBio

Kenneth Warrington

Sr. Director, Business Development,
GenScript ProBio

Ken Warrington, PhD joined GenScript Probio in 2020 as Head of Strategy & Innovation and a Sr. Director of Business Development supporting their Gene & Cell Therapy CMC services.  Dr. Warrington served on the faculty at the University of Florida focused on AAV vector development and transitioned into industry where he has served lead technical operation and business development roles for global contract testing and manufacturing organizations.  He is a co-founder and director of Lacerta Therapeutics and Chair of the Scientific Advisory Board at Biostem Life Sciences.  He has broad expertise across the viral vector product development continuum from discovery through GMP-compliant manufacturing to support IND-enabling preclinical and early stage clinical programs.

 

Dr. Avery Posey

Department of Pathology and Laboratory Medicine
University of Pennsyvania

Dr. Avery Posey

Department of Pathology and Laboratory Medicine
University of Pennsyvania

Dr. Avery Posey

Department of Pathology and Laboratory Medicine
University of Pennsyvania
 

Marie Berger

PharmD
Myriade

Marie Berger

PharmD
Myriade

Marie Berger

PharmD
Myriade

WHO WILL BE THERE

Network with industry experts from:

  • Big pharma and biotech
  • Cell Therapy Academics and clinicians 
  • Process standardisation - technology/services
  • Logistics companies - cell storage/transport
  • Service providers - CRO’s, Consultants, Government

Past attendees include:

2021 Agenda

Please fill in your details to download the Sample Agenda of 5th Annual OCTS Agenda. The OCTS EU 2022 Agenda is launching soon.

octs_front_cover.png

Last year OCTS Global ran as two seperate events, CAR-T Congress EU and Vein-to-Vein EU. Take a look at the highlights and what people thought of the event.

Download agenda

Resources

Download Resource

2021 Expertise Partners

2021 Tech Showcase Partner

2021 Event Partners

2021 Media Partners

Become a Partner

Kisaco Research provides the much-needed platform on which industry executives can network, connect and learn from each other as well as meet potential industry partners.

Far from the typical ‘meet-and-greet’ exhibition experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list.

With our extensive marketing experience and strategy, your partnership with Kisaco Research will grant you a sponsorship package that is an extension and enhancement of your current marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets – that’s why we take special care in finding the most relevant end-users to attend, so that your financial and resource investment is smartly allocated.

Find out more by calling us at +44 (0)20 3696 2920 or email us at [email protected].

Sending Your Team? Group Discounts Available!

Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920

We accept the following cards through Stripe:
Preparing registration...

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.

Contact Us